|
Multicenter Unsustained Tachycardia Trial (MUSTT) Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Multicenter Unsustained Tachycardia Trial (MUSTT) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Multicenter Unsustained Tachycardia Trial (MUSTT) Clinical research trials and Multicenter Unsustained Tachycardia Trial (MUSTT) healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Multicenter Unsustained Tachycardia Trial (MUSTT). Multicenter Unsustained Tachycardia Trial (MUSTT) Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Multicenter Unsustained Tachycardia Trial (MUSTT) clinical trial. Human subjects often receive the most effective healthcare possible for their Multicenter Unsustained Tachycardia Trial (MUSTT) condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Multicenter Unsustained Tachycardia Trial (MUSTT)  Multicenter Unsustained Tachycardia Trial (MUSTT)
Multicenter Unsustained Tachycardia Trial (MUSTT)
For Condition: Arrhythmia,Cardiovascular Diseases,Coronary Disease,Death, Sudden, Cardiac,Heart Diseases,Myocardial Ischemia,Tachycardia, Ventricular
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine the value of electrophysiologic (EP)-guided antiarrhythmic therapy in coronary heart disease patients at increased risk for sudden death. The study included a controlled clinical trial and a registry.
Details: BACKGROUND: Cardiac arrest (sudden cardiac death) occurs relatively frequently in asymptomatic patients who have had myocardial infarctions, have ejection fractions less than 40 percent, and non-sustained ventricular tachycardia. However, it is not possible to predict who will die suddenly or when cardiac arrest will occur. Current efforts to reduce sudden death in such long-term survivors of myocardial infarction or in patients with coronary disease have produced results that are not very encouraging. Such patients may feel quite well. They survived their myocardial infarction and may have slight or even moderate reduction of exercise ability, but by 'pacing' themselves, such patients can lead relatively normal lives. They may be aware of their arrhythmia because of short periods of palpitations which may only trouble them transiently. Consequently, this group of patients, many still in the prime of their lives, are at relatively high risk of dying suddenly. The multicenter trial may reveal the most effective treatment for such patients, the value of electrophysiologic studies in predicting who is most at risk of sudden cardiac death, and whether electrophysiologic studies can help select the best mode of treatment. The protocol for performing programmed stimulation and serial drug testing is designed to mirror those currently in use by many practicing electrophysiologists. DESIGN NARRATIVE: Randomized, non-blind. Patients were assigned to standard therapy or to an aggressive arm consisting of electrophysiologic-guided antiarrhythmic therapy. Patients in the aggressive arm whose ventricular tachycardia was suppressible or who were still inducible, but who were hemodynamically stable in ventricular tachycardia, were followed on drug therapy. Otherwise, patients in the aggressive arm received an implantable defibrillator. The primary endpoint was sudden cardiac death or cardiac arrest. Patients without inducible sustained ventricular tachycardia were followed in a registry. Recruitment ceased on October 31, 1996 after a recommendation from the DSMB.
Eligibility:
Study Type: Interventional, Treatment, Randomized
Minimum Age/Maximum Age: 18 Years/75 Years
Genders: Both
Protocol Entry Criteria: Men and women patients with documented coronary artery disease, ejection fraction less than or equal to 40 percent, and nonsustained asymptomatic ventricular tachycardia.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
KerryLee, , Duke University
Additional Information:
Study ID Numbers: 70;
Study Start Date: September 1991
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000480
Other Coronary Disease Studies:
1. Fatty Acid Antiarrhythmia Trial (FAAT)
2. Antiarrhythmic Effects of N-3 Fatty Acids
3. Multicenter Unsustained Tachycardia Trial (MUSTT)
Related Studies:
Other Coronary Disease Clinical Trials
Other Clinical Trials
Other Clinical Trials
Multicenter Unsustained Tachycardia Trial (MUSTT)
|
|
|
|
|
|
|
|
